9 research outputs found
Structuring connections for landscape care. The case of Casilino Ecomuseum in Rome
No full textThe ongoing environmental and social crises, amplified by the pandemic, highlight the urgent need for of new development models, based on sustainability, participation and subsidiarity. In this context, cultural institutions play a fundamental role, facilitating the construction of social capital. The case of ecomuseums is emblematic, because they offer methods, tools and practices for the recognition of local identities, co-design, care and management of the landscape and its economic value as well. The contribution supplies the framework of these ecomuseum tools, with a focus on the Casilino Ad Duas Lauros Ecomuseum in Rome, at the forefront in the realisation of physical connections to make its District a green infrastructure, virtual connections to create narrations and links of meaning and digital connections to promote social inclusion and participation
In Rural Villages and the Suburbs. Italian Experiences with Museums and Ecomuseums
No full textTwo heritage-making processes, from very different contexts of rural and urban Italy, improve our vision and understanding of the connection between the museum paradigm/experience and the intangible cultural heritage (ICH) safeguarding challenges. On the one hand, the Casa Lussu experience shows the importance of local museums s buildings blocks of a traditional weaving revitalization project. On the other hand, the Casilino Ecomuseum is ad example of a community-based ICH process in an urban context, and the pertinence of the ecomuseum paradigm to deal with such complexity
Updating obesity management strategies: an audit of Italian specialists
No full text: Obesity negatively affects physical and psychological health and increases health care costs. Although there is increasing interest in early diagnosis and timely intervention, there are several principles of care included in the current guidelines for clinical management of obesity that can potentially be updated and improved to address the "clinical inertia" and, consequently, to optimize the management of adult obesity. Using an online Delphi-based process, an Italian board of experts involved in the management of obesity discussed the usefulness of a pro-active approach to the care of patients with obesity, providing a consensus document with practical indications to identify risk factors for morbidity and death and raise awareness throughout the treatment continuum, including the early stages of the disease. In clinical practice, it seems inappropriate to delay an intervention that could avoid progression to a more severe level of obesity and/or prevent the onset of obesity-related comorbidities.Level of evidence Level V, report of expert committee
Lack of Influence of the Androgen Receptor Gene CAG-Repeat Polymorphism on Clinical and Electrocardiographic Manifestations of the Brugada Syndrome in Man.
No full textBackground: Clinical studies suggest that testosterone (T) plays an important role in the male predominance of the clinical manifestations of the Brugada syndrome (BS). However, no statistically significant correlations have been observed between T levels and electrocardiogram (ECG) parameters in the BS patients. We investigated whether the hormonal pattern and the variation within CAG repeat polymorphism in exon 1 of the androgen receptor (AR) gene, affecting androgen sensitivity, are associated with the Brugada ECG phenotype in males. Methods and Results: 16 male patients with BS (mean age 45.06 ± 11.3 years) were studied. 12-lead ECG was recorded. Blood levelsof follicle-stimulating hormone, luteinizing hormone, prolactin, testosterone, free-T, dihydrotestosterone, 17-β-estradiol, estrone, 3-alpha-androstanediol-glucuronide, delta-4-androstenedione, dehydroepiandrosterone sulphate, progesterone, 17- hydroxyprogesterone, and sex hormone binding globulin were assayed. Genotyping of CAG repeats on DNA extracted from leukocytes was carried out. No relationship was found between hormone values and ECG parameters of BS. BS patients showed the CAG length normally recognized in the human polymorphism range and the number of CAG repeats did not correlate with the ECG pattern of BS. Conclusions: The AR CAG repeat length does not correlate with the ECG features of the patients affected by BS. The search for genes downstream AR activation as possibly responsible for the increased risk of spontaneous arrhythmias in BS males after puberty is warranted. © the author(s), publisher and licensee Libertas Academica Ltd
RETI REGIONALI PER LA PREVENZIONE E CURA DELL’OBESITÀ
No full textLa rilevanza epidemiologica e clinica dell’obesità, oggi pienamente riconosciuta come una malattia cronica ad alto impatto sulla sopravvivenza e sullo stato di salute dell’individuo e della popolazione, impone la necessità di organizzare schemi e percorsi di trattamento in linea con il concetto di cronicità.
Il modello di Rete Assistenziale è il modello che risponde meglio a questa esigenza, garantendo un approccio multidisciplinare e multi-professionale ed una presa in carico globale del paziente con obesità fin dall’inizio del percorso di cura, garantendone gli aspetti logistici e organizzativi.
Il percorso di nascita della Rete Obesità Veneto può fornire uno spunto ed un esempio, pur nel dovuto rispetto della differenziazione regionale, per l’implementazione di un sistema di rete assistenziale dedicato alla prevenzione ed alla cura dell’obesità in tutte le realtà regionali
Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine
No full textTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
No full textBackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
No full textTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
No full textBackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)
